

2 March 2026

Correction on Appendix 4D

Botanix Pharmaceuticals Ltd (ABN 70 009 109 755) (ASX: BOT) (**Botanix** or the **Company**) advises that the prior corresponding period revenue figure disclosed in the Appendix 4D included a typographical error. The correct revenue for the half year ended 31 December 2024 should have been \$345,673. An updated Appendix 4D is attached to this announcement for clarity.

The Company confirms that this correction relates solely to a typographical error within the Appendix 4D and does not impact the financial statements, results announcement, or any other previously released information.

Release authorised by:

Vince Ippolito
Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries

Hannah Howlett
P: +61 4 5064 8064
investors@botanixpharma.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

For personal use only

Results for Announcement to the Market
Appendix 4D – Half Year Report

	% Change	Dec 2025 \$	Dec 2024 \$
Revenue from ordinary activities	4,675%	16,505,825	345,673
Profit / (loss) before income tax expense	7.47%	(33,195,409)	(30,888,119)
Profit / (loss) after income tax	7.47%	(33,195,409)	(30,888,119)
<u>Attributable to:</u> Equity holders of the parent		(33,195,409)	(30,888,119)
Other comprehensive income after income tax expense		(475,456)	3,588,238
Total comprehensive income after income tax expense		(33,670,865)	(27,299,881)
<u>Attributable to:</u> Equity holders of the parent		(33,670,865)	(27,299,881)

Net tangible assets per ordinary share (cents) ⁽¹⁾	1.39	2.71
---	-------------	------

	2025 \$	2024 \$
Basic earnings per share continuing operations	(1.69)	(1.70)
Diluted earnings per share continuing operations	(1.69)	(1.70)
Final dividend in respect of the period ended 30 June per share	Nil	Nil
Interim dividend in respect of the period ended 31 December per share	Nil	Nil

(1) Net tangible assets include right-of-use lease assets

For personal use only